UNICA IRIS Institutional Research Information System

MULAS, OLGA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 345.253
NA - Nord America 5.296
AS - Asia 2.778
SA - Sud America 486
Continente sconosciuto - Info sul continente non disponibili 278
AF - Africa 106
OC - Oceania 10
Totale 354.207
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 342.046
US - Stati Uniti d'America 5.092
NL - Olanda 1.913
SG - Singapore 1.078
CN - Cina 756
BR - Brasile 352
SE - Svezia 345
VN - Vietnam 261
FI - Finlandia 210
DE - Germania 194
GB - Regno Unito 126
HK - Hong Kong 125
FR - Francia 118
CA - Canada 113
KR - Corea 112
IN - India 89
UA - Ucraina 66
BD - Bangladesh 63
AR - Argentina 54
PL - Polonia 42
AT - Austria 40
JP - Giappone 39
RU - Federazione Russa 37
MX - Messico 35
ZA - Sudafrica 33
IQ - Iraq 32
TR - Turchia 27
SA - Arabia Saudita 22
EC - Ecuador 21
ES - Italia 20
PK - Pakistan 20
IR - Iran 19
MA - Marocco 18
IL - Israele 17
LT - Lituania 15
VE - Venezuela 15
CZ - Repubblica Ceca 13
ET - Etiopia 13
ID - Indonesia 13
MY - Malesia 12
PH - Filippine 12
AE - Emirati Arabi Uniti 11
IE - Irlanda 11
JM - Giamaica 11
UZ - Uzbekistan 10
CL - Cile 9
CO - Colombia 9
JO - Giordania 9
AU - Australia 8
BE - Belgio 8
BO - Bolivia 8
EG - Egitto 8
UY - Uruguay 8
KZ - Kazakistan 7
TH - Thailandia 7
CH - Svizzera 6
CR - Costa Rica 6
CW - ???statistics.table.value.countryCode.CW??? 6
OM - Oman 6
PR - Porto Rico 6
RO - Romania 6
TN - Tunisia 6
HN - Honduras 5
LB - Libano 5
NG - Nigeria 5
NI - Nicaragua 5
PE - Perù 5
TW - Taiwan 5
AZ - Azerbaigian 4
BY - Bielorussia 4
GP - Guadalupe 4
GT - Guatemala 4
NP - Nepal 4
PY - Paraguay 4
RS - Serbia 4
SC - Seychelles 4
DZ - Algeria 3
HU - Ungheria 3
KE - Kenya 3
PA - Panama 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
AL - Albania 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GE - Georgia 2
GR - Grecia 2
KG - Kirghizistan 2
KW - Kuwait 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
QA - Qatar 2
Totale 353.912
Salva come PNG Salva come JPEG
Città #
Cagliari 319.307
Uta 21.912
Amsterdam 1.869
Ashburn 871
Singapore 567
San Jose 377
Dallas 335
Fairfield 232
Boardman 229
New York 222
Los Angeles 177
Helsinki 172
Beijing 156
Council Bluffs 155
Nyköping 145
Woodbridge 134
Houston 124
Chandler 123
Seattle 121
Hong Kong 115
Santa Clara 114
Cambridge 103
Wilmington 94
Milan 92
Shanghai 87
Ho Chi Minh City 81
Rome 78
Hefei 77
Seoul 76
Ann Arbor 65
Lauterbourg 56
The Dalles 54
Hanoi 53
Columbus 39
Munich 39
São Paulo 37
Tokyo 37
Toronto 36
Boston 34
Chicago 34
Atlanta 33
Buffalo 33
Incheon 33
Warsaw 32
Denver 31
Orem 31
Nuremberg 29
Frankfurt am Main 28
London 27
Phoenix 25
Brooklyn 24
Montreal 23
San Diego 23
Dearborn 21
Jacksonville 21
Redondo Beach 21
Vienna 21
Rio de Janeiro 20
Johannesburg 19
Guangzhou 18
Lappeenranta 17
Dong Ket 16
Turku 16
Bologna 15
Chennai 15
Redwood City 15
Da Nang 14
Naples 14
Düsseldorf 13
Mumbai 13
Nanjing 13
Poplar 13
San Francisco 13
Addis Ababa 12
Haiphong 12
Mexico City 12
North Bergen 12
Baghdad 11
Buenos Aires 11
Krefeld 11
Manchester 11
Paris 11
Philadelphia 11
Shenzhen 11
Turin 11
Wuhan 11
Jeddah 10
Princeton 10
Washington 10
Amman 9
Detroit 9
Istanbul 9
Kingston 9
Miano 9
Pune 9
Stockholm 9
Tashkent 9
Vilnius 9
Ankara 8
Casablanca 8
Totale 349.603
Salva come PNG Salva come JPEG
Nome #
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome 242.345
Infectious Complications in Autoimmune Hemolytic Anemia: A Multi-Center Italian Experience 33.718
Association of Hypometilating Agents (HMA) plus Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine 3.486
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 3.443
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.357
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 3.337
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 3.255
Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study 2.936
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.898
Ruolo del trapianto allogenico nelle talassemie 2.840
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.625
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.276
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 2.207
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 2.144
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 2.131
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.963
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.886
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.850
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 1.814
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.705
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.634
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.557
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.517
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 1.039
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors 1.038
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 961
Conditioning Regimens in Patients with β-Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review 938
Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis 928
Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura 923
Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy 897
Risk and Response-Adapted Treatment in Multiple Myeloma 860
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis 848
Health-Related Quality-of-Life Profile of Pediatric Patients with β Thalassemia after Hematopoietic Stem Cell Transplantation 822
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension 817
Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials 772
Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib? 754
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study 751
Long-term health-related quality of life in patients with beta-thalassemia after unrelated hematopoietic stem cell transplantation 713
Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine 707
Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation 685
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 681
Low adherence to therapy and co-morbid depressive episodes are independent determinants of early death in people with cancer 678
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia 678
CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia 658
Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation 651
Adherence to treatment in patients with solid and hematological cancers. Could spiritual and psychological support facilitate optimal adherence? 647
Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report 589
Long-Term Health-Related Quality of Life and Clinical Outcomes in Patients with β-Thalassemia after Splenectomy 565
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML 515
Understanding the user's point of view: when the doctor gets sick with cancer and seeks help 510
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network 501
Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules 482
Systematic Review and Meta-Analysis of Health-Related Quality of Life in Patients with β-Thalassemia Underwent Hematopoietic Stem Cell Transplantation 469
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 462
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 458
The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia 449
On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML) 433
Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform 386
Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura 377
Increase of Arterial Stiffness in Patients with Polycythemia Vera 358
Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase 343
Response to Dr. Ying Cui comments 325
Arterial Stiffness as a New Predictor of Clinical Outcome in Patients with Polycythemia Vera 224
Impact of primary cancer history and molecular landscape in therapy-related myeloid neoplasms 221
Thrombotic and Infectious Complications in Patients with Autoimmune Hemolytic Anemia: A Multicenter Observational Study 215
Exploring few-shot object detection on blood smear images: a case study of leukocytes and schistocytes 178
VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management 163
Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions 144
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study 96
Health‐related quality of life and symptom profile of patients with BCR::ABL1‐negative myeloproliferative neoplasms: Real‐world evidence from the GIMEMA‐PROPHECY observational study 91
The role of satisfaction with care among factors affecting health-related quality of life in people with cancer: a cross-sectional study 88
Early Diagnosis of Gaucher Disease and ASMD in Sardinia: the “ICHNOS” Project 81
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists 78
Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study 23
Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network 13
Totale 354.207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 385.139
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 385.139
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.189 0 0 0 0 437 382 265 281 533 736 903 652
2022/20237.277 430 861 931 581 539 826 413 599 506 521 712 358
2023/20248.692 389 300 383 540 675 1.558 1.186 666 556 612 866 961
2024/2025298.477 9.454 105.120 175.909 2.949 1.092 1.464 1.375 90 321 188 171 344
2025/20268.371 501 358 638 648 478 462 1.332 352 2.340 606 380 276
2026/20271.828 183 316 480 755 94 0 0 0 0 0 0 0
Totale 354.207